Stress-Induced Dysglycemia During Vasopressor Therapy: Clinical Insights and Management Strategies

Abstract

Stress-induced dysglycemia, encompassing both hyperglycemia and hypoglycemia, is a common and clinically significant metabolic derangement observed in critically ill patients receiving vasopressor therapy. This review synthesizes current scientific evidence, elucidates the epidemiology, pathophysiology, and risk factors associated with stress-induced dysglycemia during vasopressor use, and discusses diagnostic strategies and management approaches. Emphasis is placed on the clinical implications, emerging therapies, and guideline-based recommendations for optimizing glucose control in this complex patient population.

Introduction

Stress-induced dysglycemia refers to acute fluctuations in blood glucose levels that occur in response to severe illness, physiological stress, or pharmacologic interventions, particularly in critically ill patients. Vasopressors, commonly utilized for hemodynamic support in shock and critical care settings, have pronounced effects on glucose homeostasis. The interplay between vasopressor therapy, the stress response, and glycemic control has significant implications for patient prognosis, morbidity, and mortality. Understanding the mechanisms, clinical presentations, and optimal management of stress-induced dysglycemia is essential for healthcare professionals managing critically ill patients.

Epidemiology / Disease Burden

Stress-induced dysglycemia is prevalent among patients in intensive care units (ICUs), with reported incidence rates of hyperglycemia exceeding 50% and hypoglycemia occurring in 5–10% of critically ill cohorts. The use of vasopressors, such as norepinephrine, epinephrine, and vasopressin, further increases the risk of glycemic disturbances. Epidemiological studies have demonstrated that dysglycemia during vasopressor therapy is associated with increased length of ICU stay, higher rates of infection, organ dysfunction, and greater all-cause mortality. The burden is particularly significant in patients with pre-existing diabetes, sepsis, or multi-organ failure, highlighting the necessity for vigilant monitoring and proactive management.

Pathophysiology

The pathogenesis of stress-induced dysglycemia during vasopressor therapy is multifactorial. Critical illness triggers a neuroendocrine stress response characterized by increased secretion of catecholamines, cortisol, growth hormone, and glucagon, all of which promote hepatic gluconeogenesis, glycogenolysis, and insulin resistance. Vasopressors, particularly catecholaminergic agents like norepinephrine and epinephrine, potentiate these effects by stimulating beta-adrenergic receptors, further enhancing glucose production and impairing peripheral glucose uptake. Additionally, vasopressin may alter pancreatic islet cell function, contributing to both hyperglycemia and, less frequently, hypoglycemia. The cumulative effect is a dynamic alteration in glucose homeostasis that is often unpredictable and challenging to manage.

Risk Factors

Several clinical risk factors predispose patients to stress-induced dysglycemia during vasopressor therapy. These include pre-existing diabetes mellitus, obesity, advanced age, high illness severity scores (such as APACHE II or SOFA), systemic inflammatory response syndrome (SIRS), sepsis, multi-organ dysfunction, and high-dose or prolonged vasopressor administration. The concomitant use of corticosteroids and nutritional interventions, such as parenteral nutrition, can further exacerbate glycemic variability. Identifying high-risk patients is critical for tailored monitoring and intervention strategies.

Clinical Features

Clinical manifestations of stress-induced dysglycemia vary depending on the direction and severity of glucose derangement. Hyperglycemia may present insidiously, often detected on routine laboratory testing, and is associated with increased risk of infection, impaired wound healing, and immune dysfunction. In contrast, hypoglycemia presents acutely with neuroglycopenic symptoms such as confusion, seizures, or coma, and is frequently precipitated by excessive insulin administration or abrupt changes in vasopressor dosing. Importantly, critically ill patients may have blunted or atypical symptoms, necessitating regular glucose monitoring and heightened clinical vigilance.

Diagnosis

Diagnosis of stress-induced dysglycemia relies on frequent and accurate blood glucose measurement, ideally using point-of-care capillary or arterial blood sampling. Continuous glucose monitoring (CGM) systems are increasingly utilized for real-time detection of glycemic excursions in the ICU setting. Diagnostic thresholds generally define hyperglycemia as blood glucose >180 mg/dL and hypoglycemia as <70 mg/dL, though individualized targets may be warranted based on comorbidities and overall clinical context. It is essential to differentiate stress-induced dysglycemia from other causes, such as medication errors or underlying endocrine disorders, to guide appropriate management.

Treatment & Management

Effective management of stress-induced dysglycemia during vasopressor therapy requires a multifaceted approach. Glycemic targets should be individualized, balancing the risks of hyperglycemia and hypoglycemia. Current guidelines recommend maintaining blood glucose levels between 140–180 mg/dL in most critically ill patients. Insulin infusion protocols are the mainstay of therapy for persistent hyperglycemia, with frequent titration based on glucose trends and vasopressor dosing adjustments. Hypoglycemia mandates prompt recognition and immediate correction with intravenous dextrose. Optimizing nutritional support, minimizing unnecessary corticosteroid use, and judicious vasopressor titration are additional critical strategies. Multidisciplinary collaboration among intensivists, endocrinologists, pharmacists, and nursing staff is essential for safe and effective glycemic management.

Recent Advances / Emerging Therapies

Recent advances in the management of stress-induced dysglycemia include the development of closed-loop insulin delivery systems (artificial pancreas) and enhanced CGM technologies that provide continuous, real-time feedback to guide insulin titration. Novel vasopressor agents with reduced metabolic side effects are under investigation. Furthermore, pharmacogenomic approaches may allow for individualized prediction of glycemic responses to vasopressor therapy in the future. Research into anti-inflammatory therapies and agents targeting insulin resistance holds promise for mitigating stress-induced metabolic derangements at the molecular level.

Guideline Recommendations

Major critical care guidelines, including those from the Society of Critical Care Medicine (SCCM) and the American Diabetes Association (ADA), recommend regular glucose monitoring and maintaining blood glucose levels within the range of 140–180 mg/dL for most critically ill adults, including those on vasopressors. More stringent glycemic control may be considered in select populations, provided hypoglycemia can be safely avoided. Protocol-driven insulin infusion algorithms are advocated, with frequent reassessment of glucose targets and vasopressor requirements. Education and regular training of ICU staff on glycemic management protocols are strongly encouraged to reduce the incidence of adverse glycemic events.

Conclusion

Stress-induced dysglycemia during vasopressor therapy is a frequent and clinically significant complication in critically ill patients. Its recognition and management require an in-depth understanding of the underlying pathophysiology, risk factors, and the impact of vasopressor agents on glucose homeostasis. Advances in monitoring technologies, emerging therapies, and adherence to evidence-based guidelines offer opportunities to improve patient outcomes. Continued research and multidisciplinary collaboration are imperative to optimize the care of patients experiencing stress-induced dysglycemia in the context of vasopressor therapy.